Abstract： Objective To evaluate the short-term effect and side effects of GEMOX regimen in treating the patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL).Methods Twenty-seven patients with relapsed and refractory DLBCL were treated with GEMOX regimen,GEMOX regimen:gemcitabine (GEM)1000 mg/m2 IVD on day 1 and 8; oxaliplatin (L-OHP) 100 mg/m2 IVD on day 2; treatment was repeated every 3weeks with at least 2 cycles of chemotherapy for each patient.Results The response rate of relapsed group was 64.7％ (11/17) ; the median time to progression (m-TTP) was 7.5 months (95％ CI 6.8-8.2 months).The response rate of refractory group was 60.0％ (6/10) and m-TTP was 6.2 months(95％ CI 5.3-7.1 months).There were no differences between relapsed group and refractory group in the response rate,but there were differences in m-TTP.The main side effects included marrow suppression such as leucopenia and thrombocytopenia.No patients died of toxic reactions of chemotherapy.Conclusion GEMOX regimen is a safe and effective salvage regimen for the patients with relapsed and refractory DLBCL.